Miracles of Hope


LIVE LIFE Everyday


Doxorubicin Hcl

Intercalation inhibits nucleotide replication and the action of DNA and RNA polymerases. The interaction of doxorubicin with topoisomerase II to form DNA-cleavable complexes appears to be an important mechanism of doxorubicin hydrochloride cytocidal activity.
Adjuvant breast cancer
Acute lymphoblastic leukemia
Acute myeloblastic leukemia
Hodgkin lymphoma
Non-Hodgkin lymphoma (NHL)
Metastatic breast cancer
Metastatic Wilms’ tumor
Metastatic neuroblastoma
Acute lymphoblastic leukemia
Metastatic bone sarcoma
Metastatic ovarian carcinoma
Metastatic transitional cell
bladder carcinoma
Metastatic thyroid carcinoma
Metastatic gastric carcinoma
Metastatic bronchogenic carcinoma
Metastatic soft tissue sarcom
Side Effects
Mouth pain or sores
Heart problems
Red-colored urine (patient may have red-colored urine for 1 to 2 days after infusion of doxorubicin.
Risk of new cancers
Skin damage at or near the vein where doxorubicin is given
Decreased blood cell counts

Recommended Dosage for Adjuvant Breast Cancer
Recommended dosage of Doxorubicin HCL Injection is 60 mg/m2 administered as an intravenous bolus on day 1 of each 21-day treatment cycle, in combination with cyclophosphamide, for a total of four cycles.
Recommended Dosage for Other Cancers
The recommended dosage of Doxorubicin Hydrochloride Injection/for Injection when used as a single agent is 60 mg/m2 to 75 mg/m2 intravenously every 21 days.
The recommended dosage of Doxorubicin HCL Injection, when administered in combination with other chemotherapy drugs, is 40 mg/m2 to 75 mg/m2 intravenously every 21 to 28 days.
Consider use of the lower Doxorubicin dose in the recommended dosage range or longer intervals between cycles for heavily pretreated patients, elderly patients, or obese patients.
Cumulative doses above 550 mg/m2 are associated with an increased risk of cardiomyopathy.

Pack Size: 1’s
Storage (°C.):
2°-8° C

10mg/5ml Injection

50mg/25ml Injection